Unclassified Versus Well-defined Platelet Function Disorders: A Multicenter Comparison of Bleeding Patterns and...

Area of Science:

• Hematology
• Medical Genetics
• Clinical Research

Background:

• Platelet function disorders (PFDs) stem from defects in platelet receptors, granules, or signaling pathways.
• While Glanzmann Thrombasthenia (GT) and Bernard-Soulier Syndrome (BSS) are well-defined, other PFDs have less characterized bleeding phenotypes.
• Understanding the spectrum of bleeding symptoms and healthcare needs in diverse PFDs is essential for effective patient management.

Purpose of the Study:

• To delineate the bleeding phenotype of various Platelet Function Disorders (PFDs) at diagnosis and over time.
• To compare bleeding symptoms and healthcare utilization across different PFD classifications.
• To identify PFDs beyond GT and BSS that present with significant bleeding complications.

Main Methods:

• Retrospective analysis of 129 patients diagnosed with PFDs between 2015-2020 at three US Hemophilia Treatment Centers.
• Data collection included patient demographics, bleeding symptoms, and treatment utilization.
• Statistical comparisons of bleeding symptoms and treatment frequency across PFDs were performed using chi-squared or Fisher exact tests.

Main Results:

• Epistaxis was the most frequent symptom at diagnosis across most PFDs, except for platelet secretion defects where soft tissue bleeding predominated.
• Glanzmann Thrombasthenia (GT) exhibited the highest treatment burden, with 86.2% of bleeds requiring intervention.
• Hospitalizations were significantly higher in patients with GT and platelet secretion defects compared to other PFDs.

Conclusions:

• Platelet Function Disorder Not Otherwise Specified (PFD NOS) and platelet secretion defects are associated with serious bleeding risks.
• Life-threatening hemorrhages can occur in PFDs other than GT and BSS, emphasizing the need for comprehensive evaluation and monitoring.
• Further research, including genetic testing, is crucial for unclassified platelet disorders to guide management and prevent severe blood loss.